Ordinary Skin Cells Morphed into Functional Brain Cells
Paul Tesar, PhD at Case Western Reserve School of Medicine has discovered a technique that directly converts skin cells to the type of brain cells destroyed in patients with multiple sclerosis, cerebral palsy and other so-called myelin disorders. This discovery appears in the journal Nature Biotechnology.
Plan to attend MSC 2013 August 19-21, 2013 in Cleveland, OH
Online registration for MSC 2013: Adult Stem Cell Therapy and Regenerative Medicine is open and poster abstracts are being accepted for presentation both in poster format and potentially for podium presentation during the main program as well. MSC 2013 will offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. The breadth of topics from basic discovery through model validation, clinical product development, and therapeutic application, in addition to the links between academic and commercial labs, make this conference imperative for industrial researchers, academic investigators, IP and regulatory specialists, biotechnology development investors and post-doctoral and graduate students.
Learn about stem cells!
Join over 8 million users and learn about how stem cells are being used in the laboratory and in the hospital. The NCRM teamed up with Edheads, a provider of online education tools, to launch 3 web-based education modules about stem cells. The modules, based on real clinical trials, are geared toward high school students and designed to enhance classroom curriculum. They offer a highly innovative and interactive learning experience to demonstrate the nature of stem cells and their importance in medicine and the development of new therapies.
Click here for Activity 1
NCRM Receives Ohio Third Frontier Grant for Therapeutic Cell Center
Click here for Activity 2
Click here for Activity 3
The Ohio Third Frontier Commission unanimously awarded Case Western Reserve University National Center for Regenerative Medicine (NCRM), $2.4 million for its OH-Alive Innovator Platform: A Process and Manufacturing Platform for Cell Therapy. These funds must be matched by NCRM and its collaborators so this represents a total investment of $4.8 million. The OH-Alive platform will help advance Ohio as one of the leading regions for stem cell therapy in the country by establishing a facility that will provide expertise in determining optimized conditions for producing stem cells for therapeutic purposes. Read more